Compare AFBI & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AFBI | HUMA |
|---|---|---|
| Founded | 1928 | 2004 |
| Country | United States | United States |
| Employees | N/A | 184 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 134.7M |
| IPO Year | 2020 | N/A |
| Metric | AFBI | HUMA |
|---|---|---|
| Price | $22.39 | $0.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $6.19 |
| AVG Volume (30 Days) | 32.9K | ★ 10.0M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 55.42 | N/A |
| EPS | ★ 1.29 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $526.55 |
| Revenue Next Year | N/A | $202.58 |
| P/E Ratio | $17.34 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.75 | $0.55 |
| 52 Week High | $22.47 | $2.93 |
| Indicator | AFBI | HUMA |
|---|---|---|
| Relative Strength Index (RSI) | 72.89 | 41.99 |
| Support Level | $19.84 | $0.55 |
| Resistance Level | N/A | $1.27 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.18 | 0.01 |
| Stochastic Oscillator | 97.75 | 42.14 |
Affinity Bancshares Inc is a bank holding company. The bank provides a range of financial services, including checking and savings accounts, certificates of deposit, mortgage, commercial and consumer loans, and money transfer services, operating across parts of Georgia and offering specialized lending such as dental practice and indirect automobile loans across the Southeastern United States. Its business mainly involves accepting public deposits and investing them in real estate and commercial loans, as well as mortgage-backed securities. The company also gathers deposits nationwide through its virtual bank, FitnessBank, and uses additional funding sources such as Federal Home Loan Bank borrowings.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.